Search

everythinglearnresearchcommunity

for

Search:↓

An 18-year-old shared a 5-month hair transformation using RU58841 and minoxidil, reporting no side effects and crediting most regrowth to minoxidil. Opinions on RU58841 are mixed, with some users and a YouTuber moving away from it due to side effects and lack of studies.

The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

The conversation discusses managing seborrheic dermatitis (sebderm) and male pattern baldness (MPB) with treatments like finasteride, coal tar shampoo, Nizoral, and oral minoxidil. Users suggest dietary changes, regular shampooing, and using antifungal products to control sebderm before considering minoxidil.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation is about a 23-year-old man's 5-month progress using minoxidil, finasteride, and dermarolling to treat hair loss, with before and after photos taken in the same location and lighting. One commenter notes difficulty in assessing the improvement due to the way the hair is combed over the bald spots.

The conversation is a satirical discussion about using a dermaroller on the penis, with mentions of adding finasteride and doing exercises like cock pushups and planks. Some users joke about side effects and the absurdity of the topic.

An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

The user experienced hair regrowth using a combination of Minoxidil, Finasteride, and RU58841, with Minoxidil used initially and the other treatments added later. The user believes the combination of Finasteride and RU58841 contributed to the regrowth, with RU sourced from MVsupplement.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

User shares 4-month progress using finasteride, minoxidil, and microneedling for hair loss. Others discuss body hair, hair transplant possibilities, and user's treatment response.

A bodybuilder discusses homebrewing Minoxidil and RU58841 using propylene glycol or MCT. They inquire about the feasibility and potential risks of these methods.

The post and conversation are about using RU58841 mixed with Minoxidil once a night for hair loss. The user experienced side effects from Finasteride and chose RU58841 instead.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 35-year-old male experienced significant hair improvement using microneedling, finasteride, minoxidil, and keto shampoo. He adjusted his microneedling routine for better results.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

The post and conversation are about a user's progress with microneedling and minoxidil for hair loss. The user is happy with the progress and plans to continue with the treatment, without using finasteride.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

The user shared progress pictures and discussed using minoxidil, finasteride, and a dermaroller for hair loss. They experienced side effects from finasteride and considered adding it to minoxidil to reduce these effects.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.